AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nkarta Reports Q3 2025 Financial Results and Clinical Highlights for NKX019 Trial in Autoimmune Diseases
ByAinvest
Monday, Nov 10, 2025 4:10 pm ET1min read
Nkarta has reported its Q3 2025 financial results, highlighting the enrollment of the second dose-escalation cohort for its NKX019 clinical program. The company has observed deep B-cell depletion in patients treated with fludarabine and cyclophosphamide, compared to partial B-cell depletion in those receiving cyclophosphamide alone. Nkarta's cash balance stands at $316.5 million, expected to fund operations into 2029. Initial data for NKX019 in multiple autoimmune indications is expected to be presented at a medical conference in 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet